Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model


Hemophilia is treated by IV replacement therapy with Factor VIII (FVIII) or Factor IX (FIX), either on demand to resolve bleeding, or as prophylaxis. Improved treatment may be provided by drugs designed for subcutaneous and less frequent administration with a reduced risk of inhibitor formation. Tissue factor pathway inhibitor (TFPI) down-regulates the initiation of coagulation by inhibition of Factor VIIa (FVIIa)/tissue factor/Factor Xa (FVIIa/FXa). Blockage of TFPI inhibition may facilitate thrombin generation in a hemophilic setting. A high-affinity (K_D = 25pM) mAb, mAb 2021, against TFPI was investigated. Binding of mAb 2021 to TFPI effectively prevented inhibition of FVIIa/FXa and improved clot formation in hemophilia blood and plasma. The binding epitope on the Kunitz-type protease inhibitor domain 2 of TFPI was mapped by crystallography, and showed an extensive overlap with the FXa contact region highlighting a structural basis for its mechanism of action. In a rabbit hemophilia model, an intravenous or subcutaneous dose significantly reduced cuticle bleeding. mAb 2021 showed an effect comparable with that of rFVIIa. Cuticle bleeding in the model was reduced for at least 7 days by a single intravenous dose of mAb 2021. This study suggests that neutralization of TFPI by mAb 2021 may constitute a novel treatment option in hemophilia. (Blood. 2012;119(24):5871-5878)

Introduction

Hemophilia A and B are rare bleeding disorders caused by an inherited or acquired deficiency of blood clotting Factor VIII (FVIII) or IX (FIX), respectively. Patients with hemophilia are treated by IV replacement therapy with recombinant or plasma-derived human FVIII or FIX, administered either on demand, to resolve bleeding, or as prophylaxis. Unfortunately, ~30% of hemophilia patients develop inhibitory Abs toward the injected coagulation factor, rendering replacement therapy ineffective and leaving the patient at risk of bleeding. These patients are treated intravenously with bypassing agents, such as recombinant activated Factor VIIa (FVIIa; rFVIIa) or plasma-derived activated prothrombin complex concentrate (aPCC). In patients without inhibitors, prophylactic therapy administered 2 to 4 times a week reduces the number of bleeds and associated long-term complications such as hemarthrosis; however, the need for frequent IV injections tends to negatively affect patient compliance and quality of life. Thus, improved treatment for hemophilia patients may be provided by drugs that are administered subcutaneously, have a reduced risk of inhibitor formation, and require less frequent administration.

Pioneering in vitro studies and studies in a rabbit hemophilia model suggest that blockage of tissue factor pathway inhibitor (TFPI) may provide an alternative approach to the current therapy for hemophilia. The rationale for targeting TFPI is based on the assumption that blockage of TFPI function will abolish the negative feedback loop that regulates tissue factor (TF)/FVIIa-mediated Factor X (FX) activation during the initiation phase of coagulation. Thus, blockage of TFPI inhibition may restore TF/FVIIa-mediated Factor Xa (FXa) generation that is sufficient for hemostasis. Interestingly, a low TFPI level tends to normalize hemostasis and protect hemophiliacs against bleeding. The TFPI Ag level in plasma from newborns is ~23 ng/mL compared with ~55 ng/mL in adults and may contribute to the moderate bleeding diathesis in newborn hemophiliacs. Furthermore, Factor V (FV) deficiency is shown to be associated with reduced plasma levels of TFPI that similarly might explain the moderate bleeding diathesis in FV-deficiency patients.

TFPI-targeting reagents with different potential benefits are currently being evaluated as possible novel therapeutic agents. These include a sulfated polysaccharide (fucoidan) from seaweed with TFPI-dependent procoagulant activities, and a PEGylated aptamer targeted to block TFPI inhibitory function.

TFPI consists of 3 Kunitz-type protease inhibitor (KPI) domains in a tandem arrangement. The original study on TFPI inhibition applied a polyclonal Ab against TFPI. In the present article, we describe the production and characterization of a mAb that specifically blocks the binding of FXa to the second KPI domain, KPI-2, of TFPI. The KPI-2 domain is exposed on the endothelium. TFPI inhibits FXa directly by
binding with its KPI-2 domain to the active site of FXa forming a FXa:TFPI complex. The TF/FVIIa-mediated FXa generation is furthermore tightly regulated by TFPI in a process which, as a rate-limiting step, appears to involve TFPI inhibition of FXa, either when FXa is bound to the TF/FVIIa complex or in its near vicinity on the membrane. A close interaction between the TFPI KPI-2 domain and the FXa active site is essential for the FXa inhibitory action of TFPI and for the formation of an inactive TF/FVIIa/FXa/TFPI complex which prevents FXa generation. Blockage of KPI-2 will therefore prevent TFPI binding to both FXa and FVIIa/TF and, by this dual mechanism, fully abolish TFPI inhibition of the coagulation cascade.

In the present study, mAb 2021 binding with high affinity and specificity to the KPI-2 domain of TFPI was tested for neutralizing activity by in vitro clot formation in hemophilia plasma and blood. mAb 2021 was tested in vivo by IV and subcutaneous administration before induction of a bleeding in a rabbit hemophilia model. Furthermore, the Ab was administered to rabbits after induction of a bleeding and, finally, the long-term effect of a single IV dose on blood loss on induced bleedings in the rabbit model was examined.

### Methods

#### Proteins

Human recombinant TFPI was isolated from a baby hamster kidney cell line and the short form of TFPI was isolated from yeast. Rabbit recombinant TFPI was transiently expressed from human embryonic kidney cells (HEK293-6E suspension cells), and the protein was isolated from the cell supernatant by anion exchange, cation exchange, and size exclusion chromatography. Lipidated TF (Innovin) was from Dade Behring.

#### Human material

Human blood was obtained from healthy donors who were members of the Danish National Corps of Voluntary Blood Donors. Novo Nordisk A/S has been approved by the Danish National Committee on Biomedical Research Ethics (journal number H-D-2007-0055) to use donor blood for research purposes.

#### Animals

Female New Zealand White rabbits and RBF mice (RF/1CbyJ) were purchased from Charles River Laboratories. The animals were housed in colonies of 8 to 10 individuals, with controlled room temperature and humidity, and with free access to food and drinking water. The study was approved by the Danish Animal Experiments Inspectorate.

#### Immunization and ELISA screening

RBF mice were used for immunizations with full-length human TFPI. Mice with positive serum titers were killed, and the spleens were removed aseptically and dispersed to a single-cell suspension. Fusion of spleen cells and myeloma cells (Fox-NY, ATCC CRL-1732) were used either the PEG method or electrofusion. Screening for TFPI binding of the resulting hybridoma cell supernatants was performed by ELISA. Murine IgG were captured from hybridoma supernatants using an anti-mouse polyclonal Ab (pAb). The captured Abs were screened for reactivity with either biotinylated full-length human TFPI or truncated human TFPI, and the Ab-Ag complex was detected by streptavidin-HRP.

#### Functional screening assays

Screening of hybridoma clone supernatants for abrogation of TFPI inhibition of FXa activity was performed by incubating hybridoma supernatant or control IgG (polyclonal anti-TFPI) with 6nM TFPI for 30 minutes. This was followed by addition of 5nM human FXa (Enzyme Research Laboratories) and incubation for 30 minutes. Finally, 2mM S2765 (Chromogenix) was added, and the absorbance was recorded at 405 nm (SpectraMax; Molecular Devices) after 15 minutes.

Screening of hybridoma clone supernatants was also performed with an assay, which measures the combined effect of abrogating TFPI inhibition of both FXa and the FVIIa/FXa complex. This was conducted by incubating hybridoma supernatant or control immunoglobulin (IgG) with 2.5nM TFPI, 0.04nM TF (Innovin), 32nM bovine FX (American Diagnostic), and 1nM S2765 (Chromogenix) for 30 minutes. Next, 1nM rFVIIa (NovoSeven Novo Nordisk) was added and the mixture was incubated for 15 minutes. The reaction was stopped by 50% acetic acid and absorbance at 405 nm was read. The results of all samples were compared with a background (no IgG added) and full FXa activity (no TFPI added).

#### mAb 2021 cloning and expression

DNA corresponding to the mAb 2021 humanized light chain (LC; κ chain) and heavy chain (HC; IgG4 [S241P]) were synthesized and cloned into individual pTT-based expression vectors (Yves Durocher, National Research Council Canada). Back mutations were added by site-directed mutagenesis to retain the high affinity towards TFPI, LC and HC expression vectors were cotransformed into HEK293-6E cells (Yves Durocher, National Research Council Canada) using 293Fectin (Invitrogen). A production cell line for mAb 2021 was generated using CHO.K1SV cells and a glutamine synthetase–based expression system from Lonza Biologics. CHO.K1SV cells were transfected with an expression vector carrying the mAb 2021 LC and HC cDNA cassettes under cytosmevirus promoter control and the glutamine synthetase selection marker.

#### Purification of mAb 2021

Capture of mAb 2021 from CHO.K1SV cell supernatants was performed by protein A chromatography. The product was eluted with 10mM formic acid pH 3.5, and the pH was immediately adjusted to 3.7 using 0.2M citric acid. The product was kept at pH 3.7 for 30 minutes for virus inactivation. The pH was then readjusted to 7.0 and a passive anion exchange filtration was performed. Finally, mAb 2021 was concentrated to 100 g/L.

#### X-ray crystallography

The Epstein-Barr nuclear Ag–based expression system was used for transient mammalian expression of the mAb 2021 Fab fragment (Fab 2021) in HEK293 cells, and purification was performed by cation exchange chromatography. KPI-2 of TFPI, comprising residues 91-150 of TFPI and a C-terminal His6-tag, was expressed periplasmically in Escherichia coli and purified by TFPI affinity chromatography (details in supplemental Methods, available on the Blood Web site; see the Supplemental Materials link at the top of the online article). KPI-2 residues are numbered according to the bovine pancreatic trypsin inhibitor (BPTI) numbering scheme, where the 6 cysteines in TFPI KPI-2 are numbered C5, C14, C30, C38, C51, and C55. The complex between KPI-2 and Fab 2021 was prepared by mixing Fab 2021 with excess KPI-2 followed by isolation of the complex using size exclusion chromatography. Crystals of the Fab 2021:KPI-2 complex were obtained (pH 6.0, 50mM CaCl2, 100mM MES, 45% v/v PEG200) by the sitting drop method.

The X-ray crystallographic structure of the Fab 2021 in complex with the KPI-2 domain was determined to 2.0 Å resolution (details in supplemental Methods). The crystal coordinates of the Fab 2021:KPI-2 complex have been deposited in the Protein Data Bank with the accession code 4DTG.

#### Binding affinity for TFPI

Binding interaction analysis was examined by surface plasmon resonance (SPR) using a Biacore T100 instrument (GE Healthcare). Capture of hybridoma supernatants was achieved by immobilized capture mAb against the murine Fc region, IgG (Fc) Ab (GE Healthcare). Direct capture of the purified mAb was achieved by immobilization to a CM5 chip (GE Healthcare) by amine coupling. Two-fold dilutions of recombinant human full-length TFPI or human TFPI were run from 200mM to 0.05mM for binding to the immobilized mAb. Kinetics (association rate constant \(k_a\) and dissociation rate constant \(k_d\)) and binding constant \(k_a / k_d\) were determined assuming a 1:1 interaction of TFPI and mAb 2021, using the Biacore evaluation software (GE Healthcare).

Binding on human umbilical vein endothelial cells (HUVECs) was performed by incubation of cells overnight with radiolabeled mAb 2021.
mAb 2021 was labeled with $^{125}$I by the lactoperoxidase method and purified by desalting. The radio-iodinated proteins showed no apparent degradation by HPLC analysis in concentrations ranging from 3.125 pm to 400 pm in both the absence and presence of 100 nM nonradioactive mAb 2021 to determine total and nonspecific binding, respectively. After washing and lysing the cells, cell-bound radioactivity was determined. Dissociation constants $K_D$ were found by analyzing the concentration dependence of steady-state binding in the assay.

### In vitro assays measuring mAb 2021 neutralization of TFPI inhibition

Concentration-dependent neutralization of TFPI inhibition of the FVIIa/TF/FXa complex was performed by direct incubation of FX (160 nM), TFPI (1 nM), TF Innovin (10 pM), and various concentrations of mAb 2021 in a calcium-containing buffer (5 mM) for 15 minutes. The reaction was then initiated with FVIIa (0.5 nM) and the FVIIa activity was quenched after 15 minutes by EDTA (10 mM) and addition of chromogenic substrate, S2765 (Chromogenix, 0.5 mM) to measure residual FXa activity at 405 nm. FXa activity of samples was compared with a FXa activity standard without added TFPI. The assay measures the combined effect of abrogating TFPI inhibition of both FXa and the FVIIa/TF/FXa complex.

### Neutralization of TFPI on HUVECs

HUVECs were cultivated to confluence in EBM-2 medium (Clonetics) and stimulated with 20 ng/mL TNF-α and 20 ng/mL IL-1β for 2 hours before testing. Testing was performed in 25 mM HEPES, 137 mM NaCl, 3.5 mM KCl, 5 mM CaCl₂, 1 mM MgCl₂, 0.1% BSA, pH 7.4, and FX activation was followed in the presence of Ab (0-20 mM) and with addition of 50 pM FVIIa and 50 nM FX. Generation of FXa was measured with 0.6 mM of a chromogenic substrate, S2765 (Chromogenix), and calibrated toward an FXa standard curve.

A modified prothrombin time (PT) assay was used, measuring clotting time in an automated coagulation analyzer. TF (Innovin or thromboplastin) concentration was adjusted to give a clotting time of 200 seconds in normal plasma. Plasma with various concentrations of mAb 2021 was incubated for 30 minutes before clotting was initiated by recalcification.

### Thromboelastography (TEG) experiments

TEG experiments were conducted with venous citrate-stabilized blood (0.108M citrate) from 4 male volunteers. The citrated blood was incubated with sheep anti-FVIII IgG (10 human BU/mL) from Hematologic Technologies Inc. TF (Innovin or thromboplastin) concentration was adjusted to give a clotting time of 200 seconds in normal plasma. Plasma with various concentrations of mAb 2021 was incubated for 20 minutes before clotting was initiated by recalcification.

### TFPI neutralizing mAb 2021

In vitro assays measuring neutralization of TFPI inhibition of FXa amidolytic activity and the ability to abrogate TFPI inhibition of TF/FVIIa-mediated FX activation as well as TFPI inhibition of FXa activity. The grafted variable regions were cloned into a human IgG4 format, and the identified murine variable domain sequences were used as templates for Ab humanization. The resulting humanized mAb, mAb 2021, was expressed in HEK293-6E or CHOK1SV cells and purified.

### mAb 2021 binds an epitope of the KPI-2 domain covering residues essential for FXa interaction

The ability of mAb 2021 to neutralize TFPI inhibition of FXa suggests binding to TFPI KPI-2. To map this interaction in greater detail, the isolated KPI-2 domain and the fab fragment, Fab, 2021, of mAb 2021 were recombinantly produced and cocrySTALLized. The structure of the complex was solved by X-ray crystallography at 2.0-Å resolution. The Fab 2021 binding epitope on KPI-2, defined as residues in KPI-2 within a distance of 5 Å from Fab 2021, was determined by the Pocket Scan method. The Pocket Scan method identifies potential binding sites on proteins by analyzing the pocket volume and surface area of the protein.

### Results

### Selection of TFPI neutralizing mAb 2021

A high-affinity murine mAb was selected from hybridoma clones by 2 assays measuring neutralization of TFPI inhibition of FXa amidolytic activity and the ability to abrogate TFPI inhibition of TF/FVIIa-mediated FX activation as well as TFPI inhibition of FXa activity. The grafted variable regions were cloned into a human IgG4 format, and the identified murine variable domain sequences were used as templates for Ab humanization. The resulting humanized mAb, mAb 2021, was expressed in HEK293-6E or CHOK1SV cells and purified.

mAb 2021 binds an epitope of the KPI-2 domain covering residues essential for FXa interaction.
epitope on the KPI-2 domain is shown in Figure 1. The binding epitope for mAb 2021 on KPI-2 exhibits an extensive overlap with the predicted FXa contact region on KPI-2, suggesting a structural basis for the mechanism by which mAb 2021 blocks the TFPI inhibition of FXa.

**mAb 2021 binds to TFPI with high affinity**

Binding kinetics analysis of recombinant mAb 2021 was achieved by SPR. Rate constants obtained from the analysis of binding kinetics are listed in Table 1. The binding was characterized by a fast on-rate \( k_a = 4.48 \times 10^6 \text{M}^{-1}\text{s}^{-1} \) and a very slow off rate \( k_d = 1.01 \times 10^{-4} \text{s}^{-1} \), resulting in an overall dissociation constant \( K_D = k_d/k_a \) of \( 25 \pm 8 \text{pM} \). mAb 2021 was also shown to bind the isolated KPI-2 domain by SPR analysis (Table 1), with a binding constant of \( 73 \pm 13 \text{pM} \), similar to the constant estimated for full-length TFPI.

In addition to its presence in plasma, TFPI is also present on the surface of the vascular endothelium. We therefore examined the binding of \(^{125}\text{I}-\text{mAb 2021} \) to TFPI on the surface of HUVECs. The \( K_D \) was \( 123 \pm 32 \text{pM} \) (Table 1), indicating that mAb 2021 effectively interacted with TFPI exposed on endothelial cells.

**mAb 2021 neutralizes TFPI function**

Preincubation of TFPI with mAb 2021 completely abolished its inhibition of FXa in a stoichiometric manner when measured by FXa amidolytic activity (data not shown). We then tested the ability of mAb 2021 to prevent the combined inhibitory effect of TFPI assessed by a chromogenic assay measuring abrogation of TFPI inhibition of TF/FVIIa-mediated FX activation as well as TFPI inhibition of FXa activity. Full inhibition of FXa generation at 1nM

---

**Table 1. In vitro analyses of mAb 2021**

<table>
<thead>
<tr>
<th>mAb 2021</th>
<th>TFPI, n = 3</th>
<th>( 25 \pm 8 \text{pM} )</th>
</tr>
</thead>
<tbody>
<tr>
<td>TFPI binding (SPR) ( K_D )</td>
<td></td>
<td>( k_a ) ( [1/\text{M}]: 4.48 \times 10^6 \pm 1.7 \times 10^6 ) ( (k_a / k_d): 1.01 \times 10^{-4} \pm 4.1 \times 10^{-6} )</td>
</tr>
<tr>
<td>KPI-2 domain binding (SPR) ( K_D )</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cellular TFPI binding ( K_D )</td>
<td>HUVEC, n = 5</td>
<td>123 \pm 32 \text{pM}</td>
</tr>
<tr>
<td>Neutralization of TFPI inhibition of FVIIa/TF/FXa EC(_50)</td>
<td>TFPI (1nM), FVIIa, TF (Innovin), FX n = 5</td>
<td>1.20 \pm 0.07 \text{nM}</td>
</tr>
<tr>
<td>Neutralization of TFPI inhibition of FVIIa/TF/FXa on cellular surface (HUVEC) EC(_50)</td>
<td>FVIIa, FX, n = 3</td>
<td>0.11 \text{nM}</td>
</tr>
<tr>
<td>Clot time (FVIII-deficient plasma)</td>
<td>Plasma, n = 3</td>
<td>0.58 \pm 0.07 \text{nM}</td>
</tr>
<tr>
<td>Dilute prothrombin time EC(_50)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clot time (FIX-deficient plasma)</td>
<td>Plasma, n = 3</td>
<td>0.91 \pm 0.18 \text{nM}</td>
</tr>
<tr>
<td>Dilute prothrombin time EC(_50)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clot development (hemophilic whole blood)</td>
<td>Blood, n = 4</td>
<td>2.00 \pm 0.59 \text{nM}</td>
</tr>
</tbody>
</table>

**Table 2. In vitro analyses of mAb 2021**

<table>
<thead>
<tr>
<th>mAb 2021</th>
<th>TFPI, n = 3</th>
<th>( 25 \pm 8 \text{pM} )</th>
</tr>
</thead>
<tbody>
<tr>
<td>TFPI binding (SPR) ( K_D )</td>
<td></td>
<td>( k_a ) ( [1/\text{M}]: 4.48 \times 10^6 \pm 1.7 \times 10^6 ) ( (k_a / k_d): 1.01 \times 10^{-4} \pm 4.1 \times 10^{-6} )</td>
</tr>
<tr>
<td>KPI-2 domain binding (SPR) ( K_D )</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cellular TFPI binding ( K_D )</td>
<td>HUVEC, n = 5</td>
<td>123 \pm 32 \text{pM}</td>
</tr>
<tr>
<td>Neutralization of TFPI inhibition of FVIIa/TF/FXa EC(_50)</td>
<td>TFPI (1nM), FVIIa, TF (Innovin), FX n = 5</td>
<td>1.20 \pm 0.07 \text{nM}</td>
</tr>
<tr>
<td>Neutralization of TFPI inhibition of FVIIa/TF/FXa on cellular surface (HUVEC) EC(_50)</td>
<td>FVIIa, FX, n = 3</td>
<td>0.11 \text{nM}</td>
</tr>
<tr>
<td>Clot time (FVIII-deficient plasma)</td>
<td>Plasma, n = 3</td>
<td>0.58 \pm 0.07 \text{nM}</td>
</tr>
<tr>
<td>Dilute prothrombin time EC(_50)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clot time (FIX-deficient plasma)</td>
<td>Plasma, n = 3</td>
<td>0.91 \pm 0.18 \text{nM}</td>
</tr>
<tr>
<td>Dilute prothrombin time EC(_50)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clot development (hemophilic whole blood)</td>
<td>Blood, n = 4</td>
<td>2.00 \pm 0.59 \text{nM}</td>
</tr>
</tbody>
</table>

**Figure 1.** Open-book representation of mAb 2021 epitope and paratope. (Left) KPI-2 and (right) Fab 2021 are shown as surface representations. Residues colored on KPI-2 represent epitope residues. Dark green and red represent epitope residues overlapping with the predicted FXa-binding site. The overlap between the epitope and FXa-binding site include amino acid residue R15 (red), the key residue for inhibition of FXa.

Heavy and light chain paratope residues are on Fab 2021 represented by dark and light blue, respectively.

FIX indicates Factor IX; FVIIa, Factor VIIa; FVIII, Factor VIII; FX, Factor X; FXa, Factor Xa; \( k_a \), association rate constant; \( k_d \), dissociation rate constant; \( K_D \), binding constant; KPI, Kunitz-type protease inhibitor; MTG, maximum thrombus generator; SPR, surface plasmon resonance; TF, tissue factor; and TFPI, tissue factor pathway inhibitor.
TFPI was completely abolished in a concentration-dependent manner by mAb 2021, with an EC50 value of 1.20 nM.

The effect of mAb 2021 on FXa generation was also measured on HUVECs stimulated with TNF to express TF on the surface. mAb 2021 enhanced TF/FVIIa-mediated FX activation (EC50 = 0.11 nM; Table 1) suggesting that mAb 2021 was capable of blocking inhibition of TF/FVIIa by membrane-bound TFPI. The data indicate that mAb 2021 targets functionally active TFPI forms on the endothelium as well as those present in the circulating blood.

Neutralization of TFPI by mAb 2021 promotes TF-induced thrombin generation and fibrin clot formation in hemophilia plasma and whole blood

The procoagulant effect of mAb 2021 was studied using a dilute PT (dPT) assay. mAb 2021 significantly shortened the clotting time in a concentration-dependent manner (Figure 2A). Promotion of clot formation was observed in hemophilia-plasma, with EC50 values of 0.58 ± 0.07 nM (hemophilia A) and 0.91 ± 0.18 nM (hemophilia B) given in Table 1.

In TEG experiments using whole blood under hemophilic conditions, fibrin clot formation was substantially hampered, with a prolonged clotting (R) time (Figure 2B) and a decreased MTG (Figure 2C). Addition of mAb 2021 bypassed the FVIII dysfunction and restored the clotting capacity in a concentration-dependent manner as shown by an EC50 (MTG) of 2.00 ± 0.59 nM. Importantly, the donors varied substantially with respect to both R and MTG values, but displayed similar EC50 values (Figure 2B-C).

Further examination of the procoagulant effect of 10nM mAb 2021 on TF-induced coagulation in FVIII-depleted plasma supplemented with phospholipids (PS/PC) found that the addition of mAb 2021 to FVIII-deficient plasma resulted in an increased thrombin generation and shortened the lag time compared with the control experiment in the absence of Ab (Figure 3A). The presence of 10nM mAb 2021 in combination with 0.005-1.0 IU/mL rFVIII shortened the lag time and increased the maximal rate of thrombin generation in a concentration-dependent manner (Figure 3B).

Species cross-reactivity of mAb 2021

Sequence searches blasting the KPI-2 epitope amino acid sequence against known sequences revealed no other KPI domains or any other proteins with high similarity, except for KPI-2 from rabbit and monkey species. Amino acid residues defining the mAb binding epitope in the KPI-2 domain of human TFPI are all conserved in rabbit TFPI. Accordingly, mAb 2021 was shown by SPR analysis to cross-react with recombinant rabbit TFPI, with a Kd of 0.2 nM for binding. An EC50 value of 0.6 nM was measured by dPT in FVIII-depleted rabbit plasma similar to values measured in human plasma. These findings indicate that the rabbit is a suitable species for testing the in vivo efficacy of mAb 2021.

mAb 2021 dose dependently shortens bleeding time in the hemophilic rabbit model

As a model of congenital hemophilia does not exist in rabbit, we tested mAb 2021 in a rabbit model of transient hemophilia induced
by a mAb against FVIII. The FVIII-Ab neutralized rabbit FVIII and caused a dose-dependent increase in cuticle bleeding in rabbits with increasing doses of the Ab (data not shown). Rabbits made transiently hemophilic suffered a higher blood loss (16 531 ± 4735 nmol hemoglobin) compared with a prehemophilia level of normal rabbits (1157 ± 315 nmol hemoglobin; Figure 4).

IV administration 0.5-8 mg/kg of mAb 2021 to hemophilic rabbits (n = 8-20) 35 minutes before induction of bleeding resulted in a dose-dependent reduction in blood loss (Figure 4). Doses of ≥ 1 mg/kg mAb 2021 markedly reduced blood loss in this compromised hemostatic system to levels not significantly different from those observed in nonhemophilic rabbits.

**mAb 2021 shortens bleeding time 7 days after IV administration**

To examine the duration of action of mAb 2021 after IV administration, rabbits were dosed with 20 mg/kg mAb 2021 and cuticle bleeding experiments were subsequently performed in transiently Ab-induced hemophilia at 4, 7, and 10 days. Plasma mAb 2021 concentration remained above the detection limit for at least 9 days after administration (Figure 5 left axis). Accordingly, blood loss after cuticle bleeding in these rabbits was reduced to levels of 17.5% and 6.7% at 4 and 7 days, respectively, compared with corresponding blood losses in hemophilic rabbits treated with an isotype control (Figure 5 right axis). The blood loss returned toward the hemophilic level after 10 days, at which time the plasma concentration of mAb 2021 was below the detection limit.

**mAb 2021 reduces blood loss in an ongoing bleeding**

Examination of the effect of mAb 2021 on an ongoing bleed demonstrated that IV administration of 2 mg/kg mAb 2021 reduced cuticle blood loss in the rabbit hemophilia model when administered 5 minutes after induction of the bleeding. This effect was comparable with the effect of 9 mg/kg rFVIIa (Figure 6).

**mAb 2021 reduces blood loss after subcutaneous administration**

Sixteen rabbits were randomized to treatment with subcutaneous administration of 10 mg/kg mAb 2021 or isotype control Ab 24 hours before induction of a cuticle bleeding experiment. This experiment demonstrated that the bioavailability of mAb 2021 at...

---

**Figure 4. Blood loss in rabbits with Ab-induced hemophilia.** Rabbits received FVIII Ab at –45 minutes followed by pretreatment with mAb 2021 (0.5, 1, 2, 4, 8 mg/kg) or isotype control Ab 35 minutes before induction of bleeding. The bleeding was observed for 1 hour. The normal level was measured in the hemophilia control rabbits before administration of FVIII Ab. P values are compared with the hemophilia control group.

**Figure 5. mAb 2021 duration of action study.** (Left axis, line) Plasma mAb 2021 in rabbits dosed with 20 mg/kg intravenously and (right axis, bars) blood loss after cuticle bleeding induced at 4, 7, and 10 days after administration of mAb 2021, expressed as percentage of blood loss in control rabbits dosed with isotype control Ab (n = 8). *P < .05 compared with the corresponding control group.
10 mg/kg was sufficient to ensure a reduction in hemophilic bleeding (blood loss) for 24 hours compared with hemophilic rabbits treated with isotype control mAb (Figure 7).

**Discussion**

Coagulation occurs in 3 overlapping phases: initiation, amplification, and propagation. The initiation phase occurs when FVII/FVIIa from the blood binds to extravascular TF at the site of injury. FVII is activated on binding to TF, and the complex between TF and FVIIa activates FIX to FIXa and FX to FXa. This initial TF/FVIIa-mediated FXa generation is tightly regulated by TFPI. FXa is directly inhibited by TFPI, and TF/FVIIa activity is inhibited by a mechanism in which the rate-limiting step is binding via KPI-2 of TFPI to FXa in the TF/FVIIa/FXa complex or to nearby FXa on the cell surface ultimately resulting in the inactive TF/FVIIa/FXa/TFPI complex.19-21

The rationale behind the use of TFPI inhibition to treat hemophilia is based on the assumption that blockage of TFPI inhibition will abolish the negative feedback loop, regulating TF/FVIIa-mediated FX activation during the initiation phase. Thus, TFPI blockage may enhance and prolong the initial TF/FVIIa-mediated FXa generation and partially compensate for an inadequate tenase-mediated FXa generation caused by FVIII or FIX deficiency. Earlier studies indicated that inhibition of TFPI using a polyclonal anti-TFPI Ab may facilitate thrombin generation by the prothrombinase complex, especially when FXa production via the tenase complex fails under hemophilic conditions.3,4

TFPI is present in the circulation (~2.5nM) as a full-length form and partly as various truncated forms (~34 and ~41 kDa), most of which is reported to be associated with lipoprotein. Endothelial cells are the major site of TFPI production, with constitutive synthesis, expression on the cell surface, and release in circulation.9 Platelets, monocytes, and macrophages/foam cells have recently been shown to possess the ability to express TFPI.22-25 Two alternatively spliced isoforms of TFPI are expressed. TFPIα is produced as a secretable form, whereas TFPIβ attaches directly to a glycosylphosphatidylinositol anchor on cell surfaces and represents the predominant form of TFPI on the endothelium.26

Because all of these different forms of TFPI contain a KPI-2 domain, an inhibitory Ab targeting KPI-2 should bind to all functional forms of TFPI. Binding of an Ab to the FXa contact region of KPI-2 will block all functionally active TFPI forms present in the circulation and most effectively disarm TFPI feedback regulation by abolishing the inhibition by TFPI of both FXa and TF/FVIIa.15 To obtain these desired properties, we selected a mAb against the KPI-2 domain of human TFPI. The high-affinity Ab mAb 2021 presented in this study is a humanized version of a murine mAb.

The epitope of mAb 2021 binding to TFPI was mapped by solving the structure of the KPI-2-Fab 2021 complex by X-ray crystallography at 2.0-Å resolution. The epitope comprised amino acid residues R15, Y17, R32, and K34 in the KPI-2 domain crucial for interaction with FXa and previously identified as 4 of the most important residues involved in TFPI inhibition of FXa.27 The residues shared by the mAb 2021 epitope and the predicted FXa binding site are depicted in Figure 1.

In vitro characterization demonstrated that mAb 2021 completely blocked TFPI inhibition of FXa amidolytic activity, and also showed that mAb 2021 abolished TFPI inhibition of combined FXa activity and FX activation by TF/FVIIa in a purified system with lipidated TF (Table 1). In addition, mAb 2021 was shown to bind with high affinity to both soluble and cell surface–bound TFPI, supporting the hypothesis that mAb 2021 will bind to TFPI molecules whether they are free in the blood or associated with the vessel wall (Table 1).

In plasma and whole blood, mAb 2021 significantly shortened the clot time under hemophilia-like conditions in a concentration-dependent manner (Figure 2A-C). Thrombin generation studies in FVIII-deficient plasma (Figure 3) revealed that mAb 2021 stimulated TF-induced thrombin generation and markedly shortened the lag time in plasma under hemophilia-like conditions. The presence of 10nM mAb 2021 in combination with 0.005-1.0 IU/mL rFVIII shortened the lag time and improved the maximal rate of thrombin generation in a concentration-dependent manner. The procoagulant effect of mAb 2021 at low rFVIII levels was more prominent than the modest effect induced at 1 IU/mL FVIIIa (100%). This suggests that the combined effect of mAb 2021 and rFVIII may not induce a hypercoagulable state.

In vivo, mAb 2021 reduced cuticle bleeding in hemophilic rabbits (Figure 5), with a significant effect after IV administration of 1 mg/kg 35 minutes before induction of a bleeding. Furthermore, a single IV dose of 20 mg/kg of mAb 2021 provided

---

**Figure 6. Treatment of an ongoing bleed.** Blood loss in rabbits with Ab-induced hemophilia (FVIII Ab at ~45 minutes) when treated with isotype control Ab, 2 mg/kg mAb 2021, or 9 mg/kg rFVIIa 5 minutes after induction of cuticle bleeding. The bleed was observed for 1 hour. P values are compared with the hemophilia control group.

**Figure 7. Subcutaneous administration.** Blood loss in rabbits with Ab-induced hemophilia (FVIII Ab at ~45 minutes) when pretreated subcutaneously (sc.) with 10 mg/kg mAb 2021 or isotype control Ab 24 hours before induction of bleeding. The bleed was observed for 1 hour. P values are compared with the hemophilia control group.
effective plasma concentrations of mAb 2021 for at least 7 days (Figure 5). The effect of mAb 2021 was, however, not limited to the prevention of bleeding, as mAb 2021 also effectively reduced an ongoing bleed (Figure 6). The hemostatic effect achieved with 2 mg/kg mAb 2021 was comparable with the effect observed with conventional bypassing therapy with rFVIIa at a dose of 9 mg/kg. This dose of rFVIIa was previously found to normalize cuticle bleeding in hemophilic rabbits. Finally, we demonstrated a hemostatic effect in hemophilic rabbits after subcutaneous administration of mAb 2021 (Figure 7), although it was not possible to estimate the bioavailability from the present study.

More convenient treatment of hemophilia remains a challenge, and there is a medical need for new therapeutic options with improved efficacy, a longer-lasting effect, and subcutaneous administration. mAbs represent several potential advantages for the treatment of hemophilia. Abs typically have a long plasma half-life and a high subcutaneous bioavailability. Importantly, and in contrast to conventional replacement therapy, treatment with an Ab will not impose any risk of inhibitory Abs against coagulation factors. In addition to the efficacy and safety profile of a drug, convenience for the patient may represent a key discriminator between drugs as it impacts compliance and, hence, success of the treatment. In conclusion, targeting TPPI with mAb 2021 may constitute a novel principle for the treatment of hemophilia and represents an option for subcutaneous administration with no risk of inducing formation of inhibitory Abs against FVIII and FIX in the patient. mAb 2021 is presently being tested in clinical trials in hemophilia patients.

Acknowledgments

Editorial assistance to the authors during the preparation of this manuscript was provided by Sharon Eastwood (Medical Writer, PAREXEL) and was financially supported by Novo Nordisk A/S in compliance with international guidelines for good publication practice.

Authorship

Contribution: I.H. and B.B.S. were involved in planning, selection of Abs and binding, and in vitro analysis; B.L. conducted in vivo studies; J.T.C., C.J., B.O.K., A.N.B., A.G., T.E., and B.F. made screening, selection, cloning, expression, humanization, and purification of the Ab; J.B. and L.A.S. solved the 3-dimensional structure of mAb 2021; H.H.P., L.C.P., and K.W.B. made in vitro and cellular binding studies; L.H. and M.B.H. supported plasma analysis; and M.E. and S.E.B. were involved in design, planning, and supervision.

Conflict-of-interest disclosure: All authors are employed at Novo Nordisk A/S.

Correspondence: Ida Hilden, Biopharmaceuticals Research Unit, Novo Nordisk, Novo Nordisk Park, Maaloev, Denmark; e-mail: IDAH@novonordisk.com.

References